-
Mashup Score: 24
The recent approval of omalizumab for the treatment of IgE-mediated food allergy is an important step forward for the millions of food allergy patients in the United States. Through the depletion of circulating IgE and the subsequent reduction of FcεR1 on key effector cells, patients increase their tolerance to food allergens. However, omalizumab does not permit patients to eat foods that they are allergic to with impunity. Rather, it protects them from most accidental exposures. In addition, omalizumab does not cure food allergy and has not demonstrated true immunomodulation.
Source: www.jacionline.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 5Food Allergy - 16 day(s) ago
Sindy K.Y. Tang Nicolas Castaño Kari C. Nadeau Stephen J. Galli Allergists are aware of the diversity of their patients’ personal history of allergic disease(s), the potential complexity of their individual pathophysiology, and the variety of treatment interventions (comprising both immunotherapy and other suitable treatments) that can be attempted. One recent development, the possible applications of artificial intelligence (AI) to the broad field of allergic diseases, has been extensively reviewed by
Source: www.jacionline.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 0Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent - 2 month(s) ago
Despite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There is no current agreement about what elements should be included in the preparatory or consent process.
Source: www.jacionline.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 4Immunoglobulin G4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant - 2 month(s) ago
Footnotes & These authors contributed equally to this work. Affiliations Laboratory of Immunogenetics of Human Diseases, IdiPAZ Institute for Health Research, La Paz University Hospital, Madrid, Spain Innate Immunity Group, IdiPAZ Institute for Health Research, La Paz University Hospital, Madrid, Spain Interdepartmental Group of Immunodeficiencies, Madrid, Spain Footnotes & These authors contributed equally to this work. Affiliations Department of Hematology, La Palma University Hospital, Breña Alta,
Source: www.jacionline.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent - 2 month(s) ago
Despite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There is no current agreement about what elements should be included in the preparatory or consent process.
Source: www.jacionline.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 7Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials - 3 month(s) ago
Capsule Summary: Dupilumab significantly reduced urticaria activity in patients with CSU who were symptomatic despite H1-AH; with a trend towards improvement in patients with prior anti-IgE treatment. Safety was consistent with the known dupilumab safety profile.
Source: www.jacionline.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 33Long-Term Safety of Mepolizumab in EGPA: Results From the Long-Term Access Programme - 3 month(s) ago
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing/remitting disease with heterogeneous manifestations. The Phase III MIRRA RCT demonstrated the safety and efficacy of anti-IL-5 therapy mepolizumab over 52 weeks, leading to approval for EGPA in adults. Data on the extended safety profile of mepolizumab in EGPA are limited. The Long-term Access Programme (LAP;MEA116841/NCT03298061) monitored the extended safety of real-word mepolizumab use in patients with EGPA.
Source: www.jacionline.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 9
To evaluate the efficacy and safety of TLL-018, a potent and selective small molecule TYK2/JAK1 inhibitor, in chronic spontaneous urticaria (CSU) adults with inadequate response to antihistamine.
Source: www.jacionline.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study - 4 month(s) ago
The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children in the United States and Canada onto a retrospective multicenter natural history study of hematopoietic cell transplantation (HCT).
Source: www.jacionline.orgCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 0Causative mechanisms and clinical impact of immunoglobulin deficiencies in Ataxia Telangiectasia - 4 month(s) ago
Affiliations Willem-Alexander Children’s Hospital, Department of Pediatrics, Laboratory for Pediatric Immunology, Leiden University Medical Center, Leiden, the Netherlands Affiliations Willem-Alexander Children’s Hospital, Department of Pediatrics, Laboratory for Pediatric Immunology, Leiden University Medical Center, Leiden, the Netherlands Affiliations Department of Pediatric Neurology, Amalia Children’s Hospital, and Donders Institute for Brain, Cognition and Behaviour, Radboud university medical
Source: www.jacionline.orgCategories: General Medicine News, Allergy-ImmunologyTweet
Read a new review article by Casale et al, which is a practical guide for implementing omalizumab therapy for food allergy https://t.co/R6vITr2s9R